Background: Inadequate delivery of T cells into the tumour milieu, as well as a lack of specificity
and persistence of their action hinders the potential of adoptive T cell therapy (ACT).
To overcome these issues, we propose to arm T cells with synthetic agonistic receptors
(SARs) that are conditionally activated only in the presence of a target tumour associated
antigen, and a cross-linking bispecific antibody (BiAb) specific for both T cell and
tumour cell.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
P07.02
Identification
Copyright
© 2018 Published by Elsevier Inc.
